Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
International Journal of Cancer|October 14, 2014
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patientsJordan Madic, Anna Kiialainen, Francois-Clement Bidard, et al.Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid TumorsFrederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid TumorsDidier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I TrialMartin Hutchings, Franck Morschhauser, Gloria Iacoboni, et al.Investigational New Drugs|January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancerAndreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.Pageof 4